公开(公告)号：EP1778633B1

公开(公告)日：2008-12-03

申请号：EP05751820.1

申请日：2005-06-17

申请人： Biolipox AB

发明人： OLOFSSON, Kristofer ,  SUNA, Edgars Latvian Institute of Organics Synth., ,  PELCMAN, Benjamin ,  OZOLA, Vita Latvian Institute of Organic Synthesis ,  KATKEVICS, M.; Latvian Institute of Organic Syn., ,  KALVINS, Ivars Latvian Institute of Organic Syn., ,  SCHAAL, Wesley

IPC分类号： C07D209/42 ,  C07D401/12 ,  A61K31/404 ,  A61P29/00

CPC分类号： C07D401/12 ,  C07D209/42

摘要： There is provided a compound of formula: (I) wherein X, Rl, R2, R3, R4, R5, R6, R7 and R8 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.

公开(公告)号：EP1933834A1

公开(公告)日：2008-06-25

申请号：EP06794740.8

申请日：2006-10-12

申请人： Biolipox AB

发明人： PELCMAN, Benjamin ,  OLOFSSON, Kristofer ,  SCHAAL, Wesley ,  KALVINS, Ivars ,  KATKEVICS, Martins ,  OZOLA, Vita ,  SUNA, Edgars

IPC分类号： A61K31/423 ,  A61K31/4439 ,  A61K31/497 ,  A61P29/00 ,  A61P11/06 ,  C07D263/56 ,  C07D413/12

CPC分类号： A61K31/423 ,  A61K31/4439 ,  A61K31/497 ,  C07D263/57 ,  C07D413/12

摘要： There is provided the use of a compound of formula (I),wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

公开(公告)号：EP1841735A1

公开(公告)日：2007-10-10

申请号：EP05823663.9

申请日：2005-12-22

申请人： Biolipox AB

发明人： PELCMAN, Benjamin ,  OLOFSSON, Kristofer ,  KATKEVICS, M. Latvian Inst. of Organic Synthesis ,  OZOLA, Vita Latvian Institute of Organic Synthesis ,  SUNA, Edgars Latvian Inst. of Organic Synthesis ,  KALVINS, Ivars Latvian Inst. of Organic Synthesis ,  TRAPENCIERIS, P Latvian Inst. of Organic Synthesis ,  KATKEVICA, Dace Latvian Inst. of Organic Synthesis ,  SCHAAL, Wesley

IPC分类号： C07D209/42 ,  A61P11/00 ,  A61P29/00 ,  A61K31/404 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D401/12

CPC分类号： C07D401/04 ,  C07D209/42 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04

摘要： There is provided compounds of formula (I), wherein X1, Q, T, Y, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

公开(公告)号：EP1841735B1

公开(公告)日：2011-03-09

申请号：EP05823663.9

申请日：2005-12-22

申请人： Biolipox AB

发明人： PELCMAN, Benjamin ,  OLOFSSON, Kristofer ,  KATKEVICS, Martins Latvian Inst. of Organic Synthesis ,  OZOLA, Vita Latvian Institute of Organic Synthesis ,  SUNA, Edgars Latvian Inst. of Organic Synthesis ,  KALVINS, Ivars Latvian Inst. of Organic Synthesis ,  TRAPENCIERIS, Peteris Latvian Inst. of Organic Synthesis ,  KATKEVICA, Dace Latvian Inst. of Organic Synthesis ,  SCHAAL, Wesley

IPC分类号： C07D209/42 ,  A61P11/00 ,  A61P29/00 ,  A61K31/404 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D401/12

CPC分类号： C07D401/04 ,  C07D209/42 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04

摘要： There is provided compounds of formula (I), wherein X1, Q, T, Y, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

公开(公告)号：EP2102177A1

公开(公告)日：2009-09-23

申请号：EP07848492.0

申请日：2007-12-12

申请人： Boehringer Ingelheim International GmbH ,  Biolipox AB

发明人： PELCMAN, Benjamin ,  OLOFSSON, Kristofer ,  KALVINS, Ivars ,  SUNA, Edgars ,  OZOLA, Vita ,  SCHAAL, Wesley

IPC分类号： C07D263/57 ,  A61K31/423 ,  A61P11/06 ,  A61P29/00

CPC分类号： C07D263/57

摘要： There is provided the use of a compound of formula (I): wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

公开(公告)号：EP1841736A1

公开(公告)日：2007-10-10

申请号：EP05823723.1

申请日：2005-12-22

申请人： Biolipox AB

发明人： PELCMAN, Benjamin ,  OLOFSSON, Kristofer ,  KATKEVICS, Martins, Latvian Inst. of Organic Synth ,  OZOLA, Vita, Latvian Institute of Organic Synth. ,  SUNA, Edgars, Latvian Institute of Organics Synth. ,  KALVINS, Ivars, Latvian Institute of Organic Synth ,  TRAPENCIERIS, Peteris, Latvian Inst. of Org. Synth ,  KATKEVICA, Dace, Latvian Inst. of Organic Synth. ,  SCHAAL, Wesley

IPC分类号： C07D209/42 ,  A61K31/404 ,  A61P11/00 ,  A61P29/00 ,  C07D401/04 ,  C07D401/06 ,  C07D417/06 ,  C07D403/14 ,  C07D209/30 ,  C07D403/04

CPC分类号： C07D403/04 ,  C07D209/30 ,  C07D209/42 ,  C07D401/04 ,  C07D401/06 ,  C07D403/14 ,  C07D417/06

摘要： There is provided compounds of formula (I), Wherein T, Y, X1 , R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

摘要翻译： 提供式（I）化合物，其中T，Y，X 1，R 1，R 2，R 3，R 4和R 5具有说明书中给出的含义及其药学上可接受的盐，所述化合物可用于治疗 其抑制MAPEG家族成员的活性是期望和/或需要的，并且特别是在炎症的治疗中。

公开(公告)号：EP1725227A1

公开(公告)日：2006-11-29

申请号：EP05717858.4

申请日：2005-03-02

申请人： Biolipox AB

发明人： OLOFSSON, Kristofer ,  PELCMAN, Benjamin ,  NILSSON, Peter ,  SCHAAL, Wesley ,  HALLBERG, Anders, Dept. of Medicinal Chemistry

IPC分类号： A61K31/166 ,  A61P29/00

CPC分类号： A61K31/166

摘要： There is provided a use of a compound of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.